Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
Historically, the best results of allogeneic SCT have been obtained when the stem cell donor
is a human leukocyte antigen (HLA)-matched sibling, however, this is only available for
approximately 30 percent of patients in need for SCT. Alternative donor sources include
matched unrelated donor utilizing the donor registry, cord blood transplant and mismatched
donor transplant. A human leukocyte antigen (HLA)-haploidentical donor is one who shares, by
common inheritance, exactly one HLA haplotype with the recipient, and includes the biologic
parents, biologic children and full or half siblings. There is strong body of evidence
supporting the use of haplo-SCT in patient who lack a matched sibling or unrelated donor with
high rates of successful engraftment, effective Graft Versus Host Disease (GVHD) control and
favorable outcomes comparative to those seen using other allograft sources, including
HLA-matched sibling SCT. Furthermore, it provides a cost-efficient donor option in a timely
manner especially for patients who need to proceed quickly to transplant due to concern of
disease relapse/progression.